My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

146.36 -0.26 (-0.18%)
Streaming Delayed Price Updated: 1:53 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
Three of the featured stocks are closing in on record highs. 
Via Investor's Business Daily
Topics Artificial Intelligence
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.
When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
 
Via Benzinga
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
 
Via Benzinga
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. 
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. 
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Earnings Outlook For Neurocrine Biosciences
 
Via Benzinga
Unveiling 13 Analyst Insights On Neurocrine Biosciences
 
Via Benzinga
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. 
Via Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. 
Via Benzinga
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
NASDAQ:NBIX, a growth stock which is not overvalued.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable. 
Via Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
Amgen Stock Sees Relative Strength Rating Improve To 74
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.